Janssen Rips Patent Owner's Bid To Appeal Mid-Case
Celltrion Inc. shouldn't be allowed to appeal a Massachusetts federal court's decision not to dismiss Janssen Biotech Inc.'s patent lawsuit over Pfizer Inc.'s biosimilar of anti-inflammatory biologic Remicade, Janssen said Monday,...To view the full article, register now.
Already a subscriber? Click here to view full article